Urinary System Neoplasm

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell lines (DSH1 and 5637). The variant is located in the Extracellular II domain. In regards to the response to lapatinib… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variants were found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID: 9013). The patient was categorised a… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (VM-CUBI). The variant is located in the transmembrane domain. RT112 cells infected with lentiviral vectors cont… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found by RNA screening analysis in a UBC (urothelial bladder cancer) cell line (VM-CUBI). The variant is located in the transmembrane domain. Regarding the response to lapatinib, after three d… (full text at CIViC)

PMID 24971884 · de Martino et al., 2014 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID:CF0940). The patient was categorised as a “… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID:CF0977). The patient was categorised as a “… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

ERCC1 expression as evaluated by IHC in 432 patients was associated with better disease-free survival (HR 0.70, p = 0.028) and cancer specific survival (HR 0.70, p = 0.032) on multivariable analysis.

PMID 26162296 · Klatte et al., 2015 · Open in CIViC

Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy. In-vitro studies also did not show any effects.

PMID 26162296 · Klatte et al., 2015 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Supplementary Table 4; Patients ID: CF0959). The patient was ca… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

This study assessed the potential for mutated genes associated with urothelial bladder cancers as candidates for platinum-based neoadjuvant therapy. Nineteen patients (18 male, 3 female) diagnosed wit… (full text at CIViC)

PMID 32984035 · Hirotsu et al., 2020 · Open in CIViC

This study assessed the potential for mutated genes associated with urothelial bladder cancers as candidates for platinum-based neoadjuvant therapy. Nineteen patients (18 male, 3 female) diagnosed wit… (full text at CIViC)

PMID 32984035 · Hirotsu et al., 2020 · Open in CIViC

Variant found in patients that were diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Supplementary Table 4; Patients ID: CF0949, CF0982, CF3098). Th… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Supplementary Table 4; Patients ID: CF0950). The patient was ca… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Supplementary Table 4; Patients ID: CF0979). The patient was ca… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Supplementary Table 4; Patients ID: CF1005). The patient was ca… (full text at CIViC)

PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC

EML6::NTRK3 fusion is seen in cases of Infantile fibrosarcoma and congenital mesoblastic nephroma. In general, these types of tumors more commonly harbor ETV6::NTRK3 fusions.

PMID 29099503 · Church et al., 2018 · Open in CIViC

A frequent genetic alteration in congenital mesoblastic nephroma is the translocation t(12;15) resulting in a fusion of the ETV6 gene on 12p13 and the NTRK3 gene on 15p15 that occurs almost exclusivel… (full text at CIViC)

PMID 29286563 · Vokuhl et al., 2018 · Open in CIViC

In a group of 111 mesoblastic nephroma (MN) samples, 79 were were evaluable by FISH, which consisted of 38 classical MN, 29 cellular MN, and 12 mixed MN samples. 5 year relapse free survival (RFS) was… (full text at CIViC)

PMID 29286563 · Vokuhl et al., 2018 · Open in CIViC

mTOR protein levels were found to underly a circadian 24-hour rhythm regulated by time-dependent Fbxw7-mediated ubiquitination. Survival rates of tumor-bearing mice with everolimus showed time-depende… (full text at CIViC)

PMID 24253377 · Okazaki et al., 2014 · Open in CIViC

Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Of the eight patients with FGFR3-mutated bladder/urothelial cancer, one patient with FGFR1 amplification was treated wi… (full text at CIViC)

PMID 27870574 · Nogova et al., 2017 · Open in CIViC

FGFR1 expression was increased in urothelial carcinoma cell lines and patient tumours, independent of stage and grade. FGFR1 knockdown resulted in decreases proliferation and survival in some of the c… (full text at CIViC)

PMID 19458078 · Tomlinson et al., 2009 · Open in CIViC

One urothelial cell line (JMSU1) with high expression of FGFR1 was sensitive to treatment with FGFR inhibitors (SU5402, TKI258 or PD173074). IC50 values for PD173074 and TKI-258 (Dovitinib) were in n… (full text at CIViC)

PMID 21119661 · Lamont et al., 2011 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Two types of UC cell lines were compared in this study. T24 and J82 which are mesenchymal subtype and overexpress FGFR1, and RT-4 and UMUC-14, epithelial subtype which do not express FGFR1. T24 and J8… (full text at CIViC)

PMID 30326563 · Kim et al., 2018 · Open in CIViC

Phase I dose-escalation cohort of patients with advanced solid tumors in which antineoplastic therapy (NCT01703481) was no longer effective using pan-FGFR inhibitor JNJ-42756493. Among 2 urothelial ca… (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

Only 12/118(10.2%) of patients with type I papillary renal cell carcinoma expressed FGFR2 whereas 37/96 (38.5%) patients with type II papillary renal cell carcinoma(P=0.001). In addition, FGFR2 expre… (full text at CIViC)

PMID 27379982 · Tsimafeyeu et al., 2017 · Open in CIViC

In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC)

PMID 31340094 · Loriot et al., 2019 · Open in CIViC

Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and incre… (full text at CIViC)

PMID 23558953 · Wu et al., 2013 · Open in CIViC

In a pan-cancer analysis of 10,967 TCGA tumor samples across 32 cancer types, FGFR3 G370C was identified in 5 bladder urothelial carcinoma samples and was classified as an oncogenic FGFR3 mutation. G3… (full text at CIViC)

PMID 34160364 · Li et al., 2021 · Open in CIViC

In an analysis of TCGA bladder urothelial carcinoma, somatic FGFR3 G370C was recurrently identified in 3 independent tumor samples, all within the non-T-cell-inflamed subgroup. The authors described G… (full text at CIViC)

PMID 27197067 · Sweis et al., 2016 · Open in CIViC

Targeted mutation analysis on the FGFR3 gene in 297 bladder cancer patients was conducted, where 177 patients were found to harbor FGFR3 mutations. One patient was found to harbor a novel G380R mutati… (full text at CIViC)

PMID 12461689 · van Rhijn et al., 2002 · Open in CIViC

The study found that TGFβ-activated kinase 1 (TAK1) is a novel protein that interacts and is targeted by FGFR3 kinase activity. Activating mutations in FGFR3 modulate expression of genes that regulate… (full text at CIViC)

PMID 24466111 · Salazar et al., 2014 · Open in CIViC

Targeted mutation analysis on the FGFR3 gene in 297 bladder cancer patients was conducted, where 177 patients were found to harbor FGFR3 mutations. Two patients were found to harbor the K650M variant … (full text at CIViC)

PMID 12461689 · van Rhijn et al., 2002 · Open in CIViC

Targeted mutation analysis on the FGFR3 gene in 297 bladder cancer patients was conducted, where 177 patients were found to harbor FGFR3 mutations. Among those patients, one harbored the K650T variant… (full text at CIViC)

PMID 12461689 · van Rhijn et al., 2002 · Open in CIViC

The authors screened 85 superficial bladder tumor patients (35 with early-stage (stage Ta/grade 1-2) and 50 with an advanced stage (stage T1 or grade 3)) for variants in FGFR3 and TP53 genes. FGFR3 ac… (full text at CIViC)

PMID 16278391 · Zieger et al., 2005 · Open in CIViC

In this study, 52 patients with Muscle Invasive Bladder Cancer (MIBC) were randomly selected and administered neoadjuvant cisplatin and gemcitabine chemotherapy. 39 out of 52 patients showed pathologi… (full text at CIViC)

PMID 29941343 · Yang et al., 2018 · Open in CIViC

The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression.

PMID 21119661 · Lamont et al., 2011 · Open in CIViC

FGFR3 R248C promoted FGF1 and IL-3 independent cell proliferation when transduced into Ba/F3 cells whereas Ba/F3 cells with wildtype FGFR3 were IL-3 independent, but FGF1 dependent.

PMID 19381019 · Qing et al., 2009 · Open in CIViC

In a Phase 3 trial (NCT03390504), patients with metastatic or surgically unresectable urothelial carcinoma, who had FGFR2 or FGFR3 alterations erdafitinib was tested against chemotherapy (docetaxel or… (full text at CIViC)

PMID 37870920 · Loriot et al., 2023 · Open in CIViC